6533b7d2fe1ef96bd125f675
RESEARCH PRODUCT
CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome .
Miguel-angel PeralesMiguel-angel PeralesAlbert EsquirolMolly MaloyHugo Castro-malaspinaHugo Castro-malaspinaPere BarbaPere BarbaMaria Laura FoxDavid ValcárcelSergio GiraltSergio GiraltRodrigo MartinoDolores CaballeroChristina ChoChristina ChoJorge SierraJosé Luis PiñanaLucía López-corralAnn A. JakubowskiAnn A. JakubowskiCarlos SolanoFrancisco J. Márquez-malaverQin ZhouEsperanza B. PapadopoulosEsperanza B. PapadopoulosSean M. Devlinsubject
OncologyMalemedicine.medical_specialtyTransplantation Conditioningmedicine.medical_treatmentCD34GVHDGraft vs Host DiseaseAntigens CD34Lymphocyte Depletion03 medical and health sciencesMyelogenous0302 clinical medicineRecurrencehemic and lymphatic diseasesInternal medicinemedicineHumansTransplantation HomologousIn patientAgedRetrospective StudiesTransplantationHematopoietic cellbusiness.industryRICHematopoietic Stem Cell TransplantationImmunosuppressionT-cell depletionHematologyAllogeneic hematopoietic cell transplantationMiddle AgedMyeloablative Agonistsmedicine.diseaseTransplantationLeukemiaLeukemia Myeloid Acute030220 oncology & carcinogenesisMyelodysplastic SyndromesFemalebusinessT cell depletion030215 immunologydescription
Reduced-intensity conditioning (RIC) and T cell depletion (TCD) through CD34+ cell selection without the use of post-transplantation immunosuppression are 2 strategies used to reduce nonrelapse mortality (NRM) in older patients after allogeneic hematopoietic cell transplantation (allo-HCT). To compare the efficacy of the RIC and TCD approaches, we evaluated the outcomes of patients age >50 years with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) who underwent allo-HCT from an HLA-matched donor with one of these strategies. Baseline characteristics were comparable in the patients receiving TCD (n = 204) and those receiving RIC (n = 151), except for a higher proportion of unrelated donors (68% versus 40%; P 50 years with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) who underwent allo-HCT from an HLA-matched donor with one of these strategies. Baseline characteristics were comparable in the patients receiving TCD (n = 204) and those receiving RIC (n = 151), except for a higher proportion of unrelated donors (68% versus 40%; P 50 years with AML and MDS.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-05-01 |